Search

Your search keyword '"C.F. Vogelmeier"' showing total 10 results
Start Over Author "C.F. Vogelmeier"
10 results on '"C.F. Vogelmeier"'

3. Alpha1-antitrypsin deficiency in Greece: Focus on rare variants

Author

S.A. Papiris, M. Veith, A.I. Papaioannou, V. Apollonatou, I. Ferrarotti, S. Ottaviani, A. Tzouvelekis, V. Tzilas, N. Rovina, G. Stratakos, I. Gerogianni, Z. Daniil, L. Kolilekas, K. Dimakou, G. Pitsidianakis, N. Tzanakis, S. Tryfon, F. Fragopoulos, E.M. Antonogiannaki, A. Lazaratou, E. Fouka, D. Papakosta, P. Emmanouil, N. Anagnostopoulos, T. Karampitsakos, K. Vlami, M. Kallieri, P. Lyberopoulos, S. Loukides, D. Bouros, A. Bush, M. Balduyck, C. Lombard, V. Cottin, J.F. Mornex, C.F. Vogelmeier, T. Greulich, and E.D. Manali

Subjects
Pulmonary and Respiratory Medicine
Published
2023

9. Benralizumab for Chronic Obstructive Pulmonary Disease: Results of the Phase III GALATHEA Trial

Author

G.J. Criner, B.R. Celli, C.E. Brightling, A. Agusti, A. Papi, F.C. Sciurba, D.D. Sin, C.F. Vogelmeier, M. Kato, V.H. Shih, M. Jison, P. Newbold, M.J. Goldman, U.J. Martin, and null on behalf of the GALATHEA study inv

Subjects
Galathea, medicine.medical_specialty, chemistry.chemical_compound, chemistry, biology, business.industry, Internal medicine, medicine, Pulmonary disease, Benralizumab, business, biology.organism_classification, Gastroenterology
Published
2019

10. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort

Author

F.C. Trudzinski, K. Kahnert, C.F. Vogelmeier, P. Alter, F. Seiler, S. Fähndrich, H. Watz, T. Welte, T. Speer, S. Zewinger, F. Biertz, H.-U. Kauczor, R.A. Jörres, R. Bals, Andreas Stefan, Bals Robert, Behr Jürgen, Kahnert Kathrin, Bewig Burkhard, Buhl Roland, Ewert Ralf, Stubbe Beate, Ficker Joachim H, Gogol Manfred, Grohé Christian, Hauck Rainer, Held Matthias, Jany Berthold, Henke Markus, Herth Felix, Höffken Gerd, Katus Hugo A, Kirsten Anne-Marie, Watz Henrik, Koczulla Rembert, Kenn Klaus, Kronsbein Juliane, Kropf-Sanchen Cornelia, Lange Christoph, Zabel Peter, Pfeifer Michael, Randerath Winfried J, null eeger Werner, Studnicka Michael, Taube Christian, Teschler Helmut, Timmermann Hartmut, Virchow J. Christian, Vogelmeier Claus, Wagner Ulrich, Welte Tobias, and Wirtz Hubert

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Exacerbation, Partial Pressure, Medizin, Renal function, Comorbidity, Acid-Base Imbalance, Kidney Function Tests, Risk Assessment, Cohort Studies, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, DLCO, Diffusing capacity, Internal medicine, Forced Expiratory Volume, medicine, Humans, Respiratory function, 030212 general & internal medicine, Aged, COPD, Carbon Monoxide, business.industry, Middle Aged, medicine.disease, respiratory tract diseases, Respiratory Function Tests, Cross-Sectional Studies, 030228 respiratory system, Cohort, Cardiology, Disease Progression, Pulmonary Diffusing Capacity, Female, Blood Gas Analysis, Risk assessment, business, Glomerular Filtration Rate
Abstract

Rationale Alterations of acid-base metabolism are an important outcome predictor in acute exacerbations of COPD, whereas sufficient metabolic compensation and adequate renal function are associated with decreased mortality. In stable COPD there is, however, only limited information on the combined role of acid-base balance, blood gases, renal and respiratory function on exacerbation risk grading. Methods We used baseline data of the COPD cohort COSYCONET, applying linear and logistic regression analyses, the results of which were implemented into a comprehensive structural equation model. As most informative parameters it comprised the estimated glomerular filtration rate (eGFR), lung function defined via forced expiratory volume in 1 s (FEV1), intrathoracic gas volume (ITGV) and (diffusing capacity for carbon monoxide (DLCO), moreover arterial oxygen content (CaO2), partial pressure of oxygen (PaCO2), base exess (BE) and exacerbation risk according to GOLD criteria. All measures were adjusted for age, gender, body-mass index, the current smoking status and pack years. Results 1506 patients with stable COPD (GOLD grade 1–4; mean age 64.5 ± 8.1 y; mean FEV1 54 ± 18 %predicted, mean eGFR 82.3 ± 16.9 mL/min/1.73 m2) were included. BE was linked to eGFR, lung function and PaCO2 and played a role as indirect predictor of exacerbation risk via these measures; moreover, eGFR was directly linked to exacerbation risk. These associations remained significant after taking into account medication (diuretics, oral and inhaled corticosteroids), whereby corticosteroids had effects on exacerbation risk and lung function, diuretics on eGFR, BE and lung function. Conclusion Even in stable COPD acid-base metabolism plays a key integrative role in COPD risk assessment despite rather small deviations from normality. It partially mediates the effects of impairments in kidney function, which are also directly linked to exacerbation risk.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results